- Over 88% reduction in urinary incontinence episodes achieved in low dose cohort at 12 weeks
- Good tolerability with no systemic side effects
- First DNA medicine to selectively target, at the local level, a specific subtype of sensory neurons
- Fully…
EG 427 Announces Compelling Initial Topline Clinical
